4 withdrawn. 4 Phase 1, 4 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 4 | Withdrawn 4 |
| Phase 2 | 4 | Withdrawn 4 |
Follow Uveitis: new trials by email Literature Review of Uveitis trials Research Report on Uveitis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Ustekinumab for Active Sight-Threatening Uveitis Ustekinumab - Uveitis | Phase 1 / Phase 2 | Withdrawn | National Eye Institute (NEI) | 2012-07-03 | 2019-12-05 | |
| A Pilot Study of XOMA 052 in Familial Cold Autoinflammatory Syndrome / Muckle-Wells Syndrome and Behcet's Disease XOMA 052 - Muckle Wells Syndrome, Autoinflammatory | Phase 1 / Phase 2 | Withdrawn | National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) | 2010-08-27 | 2017-07-02 | |
| Pilot Study for the Evaluation of Intravitreal Infliximab in the Treatment of Uveitic Macular Edema Infliximab (intravitreal, 2.0mg/0.05ml) - Uveitic Macular Edema, Intraocular Inflammation | Phase 1 / Phase 2 | Withdrawn | Icahn School of Medicine at Mount Sinai | 10 | 2009-08-01 | 2011-06-23 |
| A Phase I/IIa Study for the Treatment of Uveitis With Iontophoresis Iontophoresis second generation Eyegate II device - Uveitis | Phase 1 / Phase 2 | Withdrawn | Asociación para Evitar la Ceguera en México | 2007-09-01 | 2024-05-30 |
Behcet Syndrome (1) · Cryopyrin-Associated Periodic Syndromes (1) · Macular Edema (1) · Panuveitis (1) · Uveitis, Anterior (1) · Uveitis, Intermediate (1) · Uveitis, Posterior (1)
Eye Diseases (4) · Uveal Diseases (4) · Cardiovascular Diseases (1) · Chronic Disease (1) · Chronic Inducible Urticaria (1) · Chronic Urticaria (1) · Cold Urticaria (1) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (1) · Disease Attributes (1) · Genetic Diseases, Inborn (1) · Hereditary Autoinflammatory Diseases (1) · Hypersensitivity (1) · Hypersensitivity, Immediate (1) · Immune System Diseases (1) · Macular Degeneration (1)
Infliximab (1) · Ustekinumab (1) · gevokizumab (1)
Asociación para Evitar la Ceguera en México (1) · Icahn School of Medicine at Mount Sinai (1) · National Eye Institute (NEI) (1) · National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) (1)
United States (2) · Mexico (1)
Farzin Forooghian, MD (1) · Hatice N Sen, M.D. (1) · Hugo Quiroz-Mercado, MD (1) · Lourdes Arellanes, MD (1) · Raul Velez-Montoya, MD (1)